REPLY
15.5.2024 14:01:32 CEST | Business Wire | Press release
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot and will showcase its transformative potential at the Milan 2024 Xchange event on May 15-16 through a live immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515336953/en/
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot. As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. (Graphic: Business Wire)
As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. A tailored roadmap, developed in collaboration with Microsoft, guides organisations through the implementation and maximisation of Copilot’s capabilities.
Understanding the importance of adoption, Reply has developed a five-step approach to ensure that the benefits of Copilot M365 are accessible to a wide corporate audience. This approach aligns with Microsoft AI Lab’s vision and focuses on integrating Copilot into daily operations effectively. The below Copilot maturity model framework aims to help customers assess their current state and their desired state with Copilot, and to identify the gaps and the actions needed to achieve their goals:
- Approach – Exploring the art of the possible, technical readiness and align with company strategy.
- Assess – Plan a pilot where we take the early-adopters on a journey with measurement qualitative and quantitative. Use those results to create a business case and roll-out plan.
- Adopt – Set-up a CoE for Copilot. Land key messages and provide training using a scenario/functional specific approach.
- Embed – Make Copilot Business as Usual at or your organisation. Manage a dynamic licensing approach and stay on top of new features.
- Extend – Bring the power of copilot to wider application.
Immersive Introduction at Milan Xchange
Held annually, Reply’s Xchange brings together technology leaders and innovators to explore the latest in digital solutions and strategies. This year, Reply will debut the “AI-Scape Room," an immersive virtual escape room experience developed by WM Reply and powered by Microsoft Copilot for Microsoft 365. This demonstration will highlight how Copilot enhances productivity, security, and collaboration within business processes through advanced AI integration.
The AI-Scape Room is designed to foster teamwork and communication as participants collaborate to solve puzzles and challenges with the assistance of Copilot’s AI-driven insights. The bespoke escape room is an opportunity for all participants to experience, explore and discover how to utilise M365 copilot as the hands-on challenges provide valuable insights into the potential of AI in enhancing workplace efficiency and engagement.
For more information on Reply’s M365 Copilot Adoption approach, the AI-Scape Room and Reply's AI-based solutions, visit: www.reply.com
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
WM REPLY
WM Reply is the Reply Group company specialising in improving employees day-to-day lives through modern workplace solutions and connecting consumers to products and experiences they love online. We support our clients from beginning to end; designing and building their solution and easing adoption. Making sure our clients are not just enjoying the benefits of the cloud but exploiting them as well. We are recognised as leaders within Sitecore, Dynamics 365, Office 365 and the products within such as SharePoint, Power Platform, Yammer and Microsoft Teams. A Microsoft Gold Partner five times over! We have a colourful team who are famous for their imagination, delivery, passion for technology and most importantly, their pride in delivery. www.wm.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515336953/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom